Article de revue
A field based evaluation of adverse events following MenAfriVac® vaccine delivered in a controlled temperature chain (CTC) approach in Benin
Introduction:
An estimated one hundred million African meningitis belt residents have received MenAfriVac(®)meningococcal serogroup A conjugate vaccine. Since October 2012 the vaccine has been licensed for use in a controlled temperature chain (CTC) approach, at temperatures of up to 40°C for up to four days. The Benin Ministry of Health conducted a pilot evaluation in one of its 34 health districts to assess whether the CTC approach was associated with increased adverse events following immunisation (AEFIs).
Auteurs
Langues
- Anglais
Année de publication
2014
Type
Article de revue
Catégories
- Gestion de programme
Maladies
- Méningite à méningocoques
Pays
- Bénin
Mots-clés
- Controlled temperature chain (CTC)
Références sur le sujet
CTC_JOURNAL